Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
D. H. Peng, B. L. Rodriguez, L. Diao, P. O. Gaudreau, A. Padhye, J. K. Ochieng, C. A. Class, J. J. Fradette, L. A. Gibson, L. Chen, J. Wang, L. A. Byers, D. L. Gibbons
This study shows that Th17 cells contribute to resistance to MEK inhibitor and anti-PD-L1 therapy in KRAS/p53 mutant lung cancers and suggests a triple combinatorial therapy to overcome resistance.
bioRxiv · Jun 7, 2020Cancer Biology